RxDoctor Payments Data

Stanley Kordisch, MD

Gynecology · Lake Charles, LANPI 1326008038

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $433, 2.2 times the $195 reported in 2019.

$2,006in general payments, 2019–2025

Across 110 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$309
  • AbbVie$266
  • Mayne Pharma Commercial LLC$258
  • Astellas Pharma US Inc$239
  • Sumitomo Pharma America, Inc.$155
  • Avion Pharmaceuticals$145
  • plus $634 from 15 others

What the payments were for

  • Food & beverage$2,006100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,006 in reported general payments places this provider in the 70th percentile of 37 gynecology providers in Louisiana.

See all gynecology providers in Louisiana

Medicare billing

Part B allowed, 2024
$22,879
Medicare patients
247
Services billed
352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron35$22,424
GemtesaVibegron13$6,907
Estradiol214$6,642
PremarinEstrogens, Conjugated13$4,123
FyavolvNorethindrone Ac/Eth Estradiol20$1,845
Estradiol (Once Weekly)Estradiol13$1,407
ValacyclovirValacyclovir Hcl35$898
Oxybutynin Chloride ErOxybutynin Chloride39$720
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet22$439
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet22$381
Zolpidem Tartrate60$371
ProgesteroneProgesterone, Micronized18$304
Hydrocortisone47$237
Levothyroxine Sodium55$228
Losartan Potassium11$225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$239$22,42435 claims
Sumitomo Pharma America, Inc.Gemtesa$155$6,90713 claims
PfizerPremarin$309$4,12313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 37 gynecology providers in Louisiana.

Other gynecology in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →